BioLargo (BLGO) 10-Q 10 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 06, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	BIOLARGO, INC.
Trading Symbol	BLGO
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		84,469,125
Amendment Flag	false
Entity Central Index Key	880,242
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 96,948	$ 154,460
Accounts receivable	7,556	5,617
Inventory	14,601	25,514
Prepaid expense	45,000	45,000
Total current assets	164,105	230,591
Other asset, net of amortization	24,617	30,077
Deferred financing fees, net	75,370
TOTAL ASSETS	264,092	260,668
CURRENT LIABILITIES
Accounts payable and accrued expenses (Note 10)	443,964	494,938
Convertible notes payable (Note 5)	283,000	250,000
Discount on convertible notes payable (Note 5)	(117,342)	(192,000)
Customer deposit	100,000	100,000
Total current liabilities	709,622	652,938
LONG-TERM LIABILITIES
Convertible notes payable, net of current (Note 5)	759,919
Discount on convertible notes payable, net of current (Note 5)	(720,229)
Total long-term liabilities	39,690
TOTAL LIABILITIES	$ 749,312	$ 652,938
STOCKHOLDERS’ EQUITY (DEFICIT)
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2014 and June 30, 2015, respectively
Common Stock, $.00067 Par Value, 200,000,000 Shares Authorized, 82,909,300 and 84,109,125 Shares Issued, at December 31, 2014 and June 30, 2015, respectively	$ 56,098	$ 55,293
Additional paid-in capital	80,412,860	78,511,529
Accumulated deficit	(81,003,461)	(79,019,719)
Non-controlling interest	49,283	60,627
Total stockholders’ equity (deficit)	(485,220)	(392,270)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 264,092	$ 260,668

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Convertible Preferred Stock, Par Value (in Dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued	0	0
Convertible Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share)	$ 0.00067	$ 0.00067
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares Issued	84,109,125	82,909,300

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Grant revenue	$ 24,232		$ 37,028
Product revenue	15,611	$ 21,086	29,486	$ 30,373
Total revenue	39,843	21,086	66,514	30,373
Cost of goods sold	7,683	8,933	14,064	11,463
Gross profit	32,160	12,153	52,450	18,910
Costs and expenses
Selling, general and administrative	859,268	948,663	1,419,793	1,556,029
Research and development	167,211	129,376	305,210	292,981
Amortization and depreciation	2,730	2,730	5,460	5,460
Total costs and expenses	1,029,209	1,080,769	1,730,463	1,854,470
Loss from operations	(997,049)	(1,068,616)	(1,678,013)	(1,835,560)
Interest expense, net	(302,919)	(3,326)	(317,073)	(309,452)
Net loss	(1,299,968)	(1,071,942)	(1,995,086)	(2,145,012)
Net loss (non-controlling interests)	(5,588)	(14,122)	(11,344)	(24,205)
Net loss (controlling interests)	$ (1,294,380)	$ (1,057,820)	$ (1,983,742)	$ (2,120,807)
Loss per common share – basic and diluted (in Dollars per share)	$ (0.02)	$ (0.01)	$ (0.02)	$ (0.03)
Weighted average common share equivalents outstanding (in Shares)	83,400,950	76,693,189	83,188,527	78,275,663

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Third-Party Vendors [Member]Common Stock [Member]	Third-Party Vendors [Member]Additional Paid-in Capital [Member]	Third-Party Vendors [Member]	Officers [Member]Common Stock [Member]	Officers [Member]Additional Paid-in Capital [Member]	Officers [Member]	Officers and Board of Directors [Member]Additional Paid-in Capital [Member]	Officers and Board of Directors [Member]	Issued as Discount [Member]Additional Paid-in Capital [Member]	Issued as Discount [Member]	Issued as Fees [Member]Additional Paid-in Capital [Member]	Issued as Fees [Member]	Common Stock [Member]Exchange for Clyra Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Exchange for Clyra Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2014														$ 55,293		$ 78,511,529	$ (79,019,719)	$ 60,627	$ (392,270)
Shares (in Shares) at Dec. 31, 2014														82,909,300
Issuance of stock in exchange of Clyra shares													$ 268		$ (268)
Issuance of stock in exchange of Clyra shares (in Shares)													400,000
Issuance of stock for non-employee services	$ 161	$ 94,549	$ 94,710	$ 376	$ 197,356	$ 197,732
Issuance of stock for non-employee services (in Shares)	238,904			560,921
Issuance of stock for services		$ 405,955	$ 405,955				$ 249,700	$ 294,700
Fair value of warrant									$ 892,919	$ 892,919	$ 61,120	$ 61,120
Net loss																	(1,983,742)	(11,344)	(1,995,086)
Balance at Jun. 30, 2015														$ 56,098		$ 80,412,860	$ (81,003,461)	$ 49,283	$ (485,220)
Shares (in Shares) at Jun. 30, 2015														84,109,125

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,995,086)	$ (2,145,012)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Amortization and depreciation expense	5,460	5,460
Increase (decrease) in cash from change in:
Accounts receivable	(1,939)	1,027
Inventory	10,913	5,100
Prepaid expenses		(45,000)
Customer deposit		100,000
Accounts payable and accrued expenses	(43,074)	(26,898)
Net Cash Used In Operating Activities	(813,362)	(1,008,763)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of financing costs	(22,150)
Net cash provided by financing activities	755,850	1,234,644
Proceeds from sale of convertible notes payable	778,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(57,512)	225,881
CASH AND CASH EQUIVALENTS — BEGINNING	154,460	92,437
CASH AND CASH EQUIVALENTS — ENDING	96,948	318,318
Cash Paid During the Period for:
Interest	9,400	6,733
Taxes	4,000	2,400
Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of stock		1,014,644
Stock in Subsidiary [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from the sale of stock		220,000
Vendors [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense, stock issued	405,955	188,463
Common Stock [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense	11,573	291,574
Warrant [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense	262,267
Issued in Conjunction with the Extension of Convertible Note Payable [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Fair value of warrants issued	892,919	584,800
Issued in Conjunction with Convertible Notes Payable for Fees [Member]
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Fair value of warrants issued	61,120
Officers and Board of Directors [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense related to options issued to board of directors	249,700	253,911
Non-cash expense, stock issued	197,732	141,425
Consultants [Member]
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash expense, stock issued	$ 83,137	$ 221,187

Note 1 - Business and Organizat

Note 1 - Business and Organization	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Business and Organization Liquidity The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, we had a net loss of $1,995,086 for the six-month period ended June 30, 2015, and at June 30, 2015, we had negative working capital of $545,517, current assets of $164,105, and an accumulated stockholders’ deficit of $81,003,461. The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract significant new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technology. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Our total cash and cash equivalents were $96,948 at June 30, 2015. We recorded revenues of $66,514 in the six-month period ended June 30, 2015, which amount was not sufficient to fund our operations. We generally have not had enough cash or sources of capital to pay our accounts payable and expenses as they arise, and have relied on the issuance of stock options and common stock, as well as extended payment terms with our vendors to operate. We will be required to raise substantial additional capital to expand our operations, including without limitation, hiring additional personnel, additional scientific and third-party testing, costs associated with obtaining regulatory approvals and filing additional patent applications to protect our intellectual property, and possible strategic acquisitions or alliances, as well as to meet our liabilities as they become due for the next 12 months. As of June 30, 2015, we had $1,042,919 principal amount outstanding on our convertible note payables (see Note 5), and $443,964 of outstanding accounts payable and accrued expenses. (See Note 10.) The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8-03 of Regulation S-X under the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for annual financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. We are still operating in the early stages of the sales and distribution process, and therefore our operating results for the six-month period ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or for any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2015.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of: December 31, 2014 June 30, 2015 Raw materials $ 18,816 $ 12,605 Finished goods 6,698 1,996 Total inventory $ 25,514 $ 14,601 Other Assets Other Assets consists of payments made to purchase patents related to our efforts in commercializing the Isan system. For the six-month periods ended June 30, 2014 and 2015, we recorded amortization expense totaling $5,460 and $5,460, respectively. We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Management has not identified any impairment indicators at June 30, 2015. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based and financing transactions, uncollectible accounts receivable, asset impairment, depreciation and amortization, and taxes, among others. Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting. During the six-month periods ended June 30, 2014 and 2015, we recorded an aggregate $442,374 and $655,655 in selling general and administrative expense related to options issued as part of our 2007 Equity Incentive Plan and outside of our 2007 Equity Incentive Plan (see Note 9). During the six-month periods ended June 30, 2014 and 2015, we issued an aggregate 284,491 and 560,921 shares of our common stock to our officers in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $166,607 and $197,732, respectively. During the six-month periods ended June 30, 2014 and 2015, we issued an aggregate 313,209 and 238,904 shares of our common stock to third party vendors in lieu of accrued and unpaid obligations totaling $229,527 and $94,710, respectively. (See Note 9). On March 28, 2014, we issued an aggregate 1,360,000 shares of our common stock to note payable holders in lieu of $584,800 note payable principal balance and related accrued interest. (See Note 5). Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. License fees are recognized over the estimated period of future benefit to the average licensee. Grants received are recognized as revenue when the terms and conditions of the grant are met on a periodic basis over the life of the grant. Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the six-month periods ended June 30, 2014 and 2015, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new, principle-based revenue recognition framework that will affect all revenue-generating activities. In addition to superseding and replacing nearly all existing revenue recognition guidance under U.S. GAAP, including industry-specific guidance, the new standard: ● changes the basis for deciding when revenue is recognized over time or at a point in time; ● provides new guidance on specific aspects of revenue recognition; and ● expands and improves disclosures about revenue. Entities are required to apply the standard for annual periods beginning after December 15, 2018, and for interim periods therein. The standard permits the use of either the retrospective method, where prior period results are reflected on a comparable basis, or cumulative effect method. Management is currently evaluating the effect of this pronouncement on its financial reporting. In August 2014, the FASB issued ASU No. 2014-15 ("ASU 2014-15"), “Presentation of Financial Statements-Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.” ASU 2014-15 requires a Company's management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory, Topic 330, Inventory.” An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU 2015-11 on its consolidated financial statements. In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02), “Consolidation” . In April 2015, the FASB issued Accounting Standards Update No. 2015-03 (ASU 2015-03), “Interest – Imputation of Interest” (Subtopic 835-30). ASU 2015-03 simplifies the presentation of debt issuance costs and requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the new guidance. ASU 2015-3 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within that fiscal year. Early adoption is permitted for financial statements that have not been previously issued. An entity is required to apply the new guidance on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company is currently evaluating the impact of the adoption of ASU 2015-03 on the Company’s financial statement presentation and disclosures.

Note 3 - Deposit

Note 3 - Deposit	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Deposit Liabilities Disclosures [Text Block]	Note 3. Deposits Royalty Revenue In 2012, we executed a joint venture agreement with Peter Holdings Ltd., the principal developer of the Isan System, whereby we jointly purchased the intellectual property associated with the Isan System, and agreed to share any royalties from any licensing revenue generated from the ISAN System on an equal 50/50 basis. In February 2014, we received a deposit of $100,000 from InsulTech Manufacturing, LLC, an Arizona limited liability company d/b/a Clarion Water (“Clarion Water”) towards a worldwide, exclusive license of the Isan System. On August 12, 2014, we entered into a license agreement with Clarion Water in which we granted an exclusive license to commercialize the Isan System. The license agreement provides that the $100,000 deposit is non-refundable, and is to be credited to future payments of royalties or sublicense fees due under the license agreement. The agreement further provides for a 10% royalty of licensee’s “net sales revenue”, and 40% of sublicensing fees. Licensee is required to make minimum payments beginning July 1, 2016, of $50,000 per quarter, and we are obligated to share any revenues under the agreement on an equal basis with Peter Holdings Pty. Ltd. The intellectual property subject to the license agreement includes all intellectual property related to the Isan System, including all patents, trademarks, proprietary knowledge, and other similar know-how or rights relating to or arising out of the Isan System or the patents related to the Isan System. The agreement contains other terms and conditions typically found in intellectual property license agreements.

Note 4 - Private Securities Off

Note 4 - Private Securities Offerings	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 4. Private Securities Offerings 2015 Unit Offering On January 15, 2015, we commenced a private securities offering of “units”, each Unit consisting of a convertible promissory note and Series A stock purchase warrant. The price and availability of the Units are set forth in a “Pricing Supplement” issued from time-to-time, and priced up to a 30% discount to the market price of the Company’s common stock. The Offering is subject to an over-allotment of 20%, or an additional $1,000,000 in Units, for an aggregate total of $6,000,000, and shall be known as the Company’s “2015 Unit Offering.” The Company has the right to register the common shares underlying the notes and warrants (“Shares”) with the Securities and Exchange Commission, and the obligation to register the Shares in the event we are successful in raising $3,000,000 of gross proceeds. (See Note 5.) Purchasers of the Units will receive an unsecured convertible promissory note bearing interest at the rate of 12% per annum on the amount invested. Any interest due will be paid quarterly in arrears in cash or shares of common stock. If paid by the issuance of common stock, interest is paid at a conversion price equal to the average closing price of the Company’s common stock over the 20 trading days prior to the interest payment due date. The principal amount of the note may be paid by the issuance of shares of common stock, or cash, upon maturity at the Company’s election. When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the Unit price, as it is established at the time of the original investment by the applicable Pricing Supplement. Notes may be converted at any time by the investor, at maturity by the Company, or by the Company prior to maturity, so long as all of the following conditions are met: (i) the Shares issued as payment are registered with the SEC, (ii) the Company’s common stock closes for ten consecutive trading days at or above three times the Unit price. Notes mature on June 1, 2018. Each Series A warrant allows for the purchase of the number of common shares equal to the investment amount divided by the Unit price, (e.g., one warrant share for each share of common stock which the investor is eligible to receive through conversion of his original convertible note) and, the warrant will have an exercise price as set forth in the Pricing Supplement. Each Series A warrant expires June 1, 2020. The Company may “call” the Series A warrant, requiring the investor to exercise the warrant within 30 days or forever lose the rights to do so, only if the following conditions have been met: (i) the underlying Shares are registered with the SEC, and (ii) the Company’s common stock closes for 10 consecutive trading days at or above two times the exercise price. Summer 2013 Private Securities Offering Pursuant to a private offering of our common stock at a price of $0.25 per share that commenced June 2013, through its expiration on March 31, 2014, we sold 3,370,000 shares of our common stock to 23 accredited investors and received $842,500 gross and $837,000 net cash proceeds from the sales. In addition, we received a subscription agreement for $20,000 through an individual retirement account, the funds for which had not been received by June 30, 2014 (but were received in the July 2014). Of the aggregate 3,370,000 shares sold in the offering, for the three-month period ended March 31, 2104, we sold 3,110,000 shares of our common stock and received $767,500 gross proceeds from the sales. Fees related to this offering consisted of $15,500 cash payments, $34,600 were paid by issuing 138,400 shares of our common stock at an exercise price of $0.25 per share. The share price on the grant date was $0.47 resulting in additional interest expense of $65,000. Each purchaser of stock received, for no additional consideration, a stock purchase warrant which entitles the holder to purchase a number of additional shares of our common stock equal to the number of shares originally purchased and is subject to a call provision in the event BioLargo’s common stock price reaches $0.60 per share over a period of 40 days. (See Note 7). Clyra Spring 2014 Private Securities Offering On February 1, 2014, our subsidiary Clyra (see Note 11) began a private securities offering, selling up to 1,000 shares of its common stock at $1,000 per share. From inception through June 30, 2014, Clyra sold 220 shares of its common stock to five accredited investors and received $220,000 gross and net proceeds from the sales. Each purchaser of stock received, for no additional consideration, (i) a stock purchase warrant entitling the holder to purchase the same number of shares of Clyra common stock as purchased in the offering for $1,833.33 per share until July 30, 2015, and (ii) a warrant issued by BioLargo that allows the holder to exchange one share of Clyra common stock for 4,000 shares of BioLargo common stock, until July 30, 2015. (See Note 7.)

Note 5 - Notes and Convertible

Note 5 - Notes and Convertible Notes Payable	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Short-term Debt [Text Block]	Note 5. Notes and Convertible Notes Payable 2015 Unit Offering In accordance with the terms of our 2015 Unit Offering (see Note 4), during the six-month period ended June 30, 2015, we received $645,000 and issued unsecured convertible promissory notes with a maturity date of June 1, 2018, which accrue interest at a rate of 12% per annum. Each investor, for no additional consideration, received a Series A stock purchase warrant exercisable at $0.40 per share, which expires June 1, 2020. (See Note 7). December/January Notes In December 2014, we received $200,000 and issued unsecured convertible promissory notes each with a one-year maturity date, which accrue interest at a rate of 12% per annum. Each noteholder, for no additional consideration, received a stock purchase warrant exercisable at $0.30 per share, which terminates three years after the date of issuance. We issued warrants to purchase an aggregate 350,000 shares. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in a $200,000 discount on the convertible note payables. Each noteholder may exchange the note for the securities offered in our current private securities offering. In January 2015, we received $133,000 and issued unsecured convertible promissory notes each with a one-year maturity date, which accrue interest at a rate of 12% per annum. Each noteholder, for no additional consideration, received a stock purchase warrant exercisable at $0.30 per share, which terminates three year after the date of issuance. (See Note 7). On April 27, 2015 a noteholder exchanged this note for a note and warrant on the terms offered in our 2015 Unit Offering (see Note 4), such that the noteholder was issued a new convertible promissory note totaling $56,610, with a due date of June 1, 2018, and a stock purchase warrant to purchase 226,440 shares at $0.40, expiring June 1, 2018. (See Note 7). On June 17, 2015 a noteholder exchanged this note for a note and warrant on the terms offered in our 2015 Unit Offering (see Note 4), such that the noteholder was issued a new convertible promissory note totaling $58,309 with an expiration date of June 1, 2018, and a stock purchase warrant to purchase 233,236 shares at $0.40, expiring June 1, 2018. (See Note 7). Line of Credit On November 19, 2013, we received $50,000 pursuant to a line of credit which accrues interest at a rate of 24%. We have pledged our inventory and accounts receivable as collateral. The maturity date of the line of credit is May 15, 2016. For the six-month periods ended June 30, 2014 and 2015, we recorded $64,665 and $317,075 of interest expense related to our line of credit, convertible notes payable and amortization of discount on convertible notes payable.

Note 6 - Conversion of Notes

Note 6 - Conversion of Notes	6 Months Ended
	Jun. 30, 2015
Conversion Of Notes [Abstract]
Conversion Of Notes [Text Block]	Note 6. Conversion of Notes On March 26, 2014, we issued an aggregate 1,360,000 shares of our common stock, at a conversion price of $0.25, resulting in a fair value of $584,800, as payment for an aggregate $275,000 in principal and $65,000 of accrued and unpaid interest expense for three promissory notes (originally issued on June 8, 2010, October 28, 2013, and November 15, 2013). Our stock price on the date of issuance was $0.43 per share, resulting in an additional financing costs of $244,800 which was recorded as interest expense during the three-month period ended March 31, 2014.

Note 7 - Warrants

Note 7 - Warrants	6 Months Ended
	Jun. 30, 2015
Warrants [Abstract]
Warrants [Text Block]	Note 7. Warrants We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following tables: Number of Shares Price Range Outstanding as of December 31, 2013 10,618,771 $ 0.125 – 2.00 Issued 4,150,001 $ 0.25 – 1.00 Exercised (574,288 ) $ 0.25 – 0.50 Expired (6,111,362 ) $ 0.50 – 1.00 Outstanding as of June 30, 2014 8,083,122 $ 0.125 – 1.00 Number of Shares Price Range Outstanding as of December 31, 2014 8,838,122 $ 0.125 - 1.00 Issued 3,670,976 $ 0.30 - 0.75 Exercised — $ — Expired (2,333,329 ) $ 0.55 Outstanding as of June 30, 2015 10,175,769 $ 0.125 - 1.00 To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model and the calculated value is amortized over the life of the warrant. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: 2014 2015 Risk free interest rate .15 % 1.32 – 1.71 % Expected volatility 112 % 329 % Expected dividend yield — — Forfeiture rate — — Contractual life in years 1 5 The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. Warrants Issued Concurrently with Convertible Note Payables During the six-month period ended June 30, 2015, we issued warrants to purchase an aggregate 266,000 shares of our common stock. These warrants are exercisable at $0.30 per share and expire January 2020. The fair value of warrants totaled $133,000 and was recorded as a discount on the convertible notes payable. Pursuant to the terms of our Convertible Notes Payable, two noteholders of the December and January convertible notes payable exchanged their notes and accrued interest for notes and warrants on the terms offered in our 2015 Unit Offering totaling $114,919 (See Note 4 & 5). With the exchange, these note holders received additional warrants to purchase an aggregate 459,676 of our common stock at an exercise price of $0.40 which expire in June 2018. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in an aggregate $114,919 discount on these new convertible notes payable. 2015 Unit Offering Warrants Pursuant to the terms of our 2015 Unit Offering (see Note 4), during the six-month period ended June 30, 2015, we issued warrants to purchase up to an aggregate 2,732,800 shares of our common stock at an exercise price of $0.40 per share. These warrants were issued to investors and as commissions, and are set to expire June 1, 2020. The fair value of the warrants and the intrinsic value of the beneficial conversion feature resulted in an aggregate $645,000 discount on the convertible notes payable. Summer 2013 Warrants Pursuant to the terms of our Summer 2013 Offering (see Note 4), since inception in June 2013 through its termination on March 31, 2014, we issued warrants to purchase up to an aggregate 3,370,000 shares of our common stock to the investors in the Summer 2013 Offering at an exercise price of $0.30 per share. Of this amount, we issued warrants to purchase up to an aggregate 3,110,000 shares of our common stock during the six-month period ended June 30, 2014. These warrants are set to expire October 15, 2015. Clyra 2014 Warrants Pursuant to the terms of the Clyra 2014 Spring Offering (see Note 4), during the six-month period ended June 30, 2014, we issued warrants to purchase up to an aggregate 880,000 shares of our common stock to the investors in the Clyra 2014 Spring Offering at an exercise price of $1,833.33 per share. These warrants expired unexercised July 30, 2015. During the six-month period ended June 30, 2015, two Clyra shareholders exercised their BioLargo warrant and tendered an aggregate 75 Clyra shares in exchange for 300,000 shares of BioLargo common stock. Subsequent to June 30, 2015, the final three Clyra investors exercised their BioLargo warrants and tendered 115 shares of Clyra common stock to BioLargo, and were issued an aggregate 460,000 shares of BioLargo common stock. All Clyra investors that participated in the Clyra 2012 and Clyra 2014 Private Securities Offering exercised tendered their shares of Clyra common stock for Biolargo common stock.

Note 8 - Stock-Based Compensati

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Compensation and Employee Benefit Plans [Text Block]	Note 8. Stock-Based Compensation and Other Employee Benefit Plans During the six-month periods ended June 30, 2014 and 2015, we recorded an aggregate $442,374 and $655,655 in selling general and administrative expense related to options issued pursuant to our 2007 Equity Incentive Plan and to options issued outside of the 2007 Plan. 2007 Equity Incentive Plan On August 7, 2007, and as amended April 29, 2011, our Board of Directors adopted the BioLargo, Inc. 2007 Equity Incentive Plan (“2007 Plan”) as a means of providing our directors, key employees and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan. The Compensation Committee administers this plan. The plan allows grants of common shares or options to purchase common shares. As plan administrator, the Compensation Committee has sole discretion to set the price of the options. The Compensation Committee may at any time amend or terminate the plan. On April 20, 2015, we issued an option to purchase 700,000 shares of our common stock to a consultant. The option vests ratably over ten-months, expires ten years from the date of issuance, and is exercisable at $0.40 per share. The price of our common stock on the grant date was $0.34 per share. The fair value of this option totaled $238,000 and is being expensed as selling, general and administrative expense over the vesting period. On June 24, 2015, our board of directors extended by five years the expiration of an option to purchase 200,000 shares of our common stock issued to our Chief Science Officer in February 2010. The option was issued in exchange for unpaid salary obligation at an exercise price of $0.575 and now expires February 5, 2020. Fair value of the option totaled $68,000 of additional selling, general and administrative expenses. On June 24, 2015, the date of our annual stockholder meeting, we recorded the issuance of options to purchase an aggregate 40,000 shares of our common stock to the non-employee members of our Board of Directors, pursuant to the terms of the 2007 Equity Plan which calls for an annual automatic issuance. The options expire ten years from the date of issuance, and are exercisable at $0.38 per share, the price of our common stock on the grant date. The fair value of these options totaled $15,200 and was recorded as selling, general and administrative expense. On June 23, 2014, the date of our annual stockholder meeting, we recorded the issuance of options to purchase an aggregate 40,000 shares of our common stock to the non-employee members of our Board of Directors, pursuant to the terms of the 2007 Equity Plan which calls for an annual automatic issuance. The options expire ten years from the date of issuance, and are exercisable at $0.63 per share, the price of our common stock on the grant date. The fair value of these options totaled $25,200 and was recorded as selling, general and administrative expense. Activity for our stock options under the 2007 Plan for the six-month period ended June 30, 2014 and 2015 is as follows: Weighted Average Options Shares Price per Price per Outstanding Available share share Balances as of December 31, 2013 8,521,086 4,260,742 $ 0.23 – 1.89 $ 0.44 Granted 40,000 (40,000 ) $ 0.63 0.63 Exercised — — $ — — Expired — — $ — — Balances as of June 30, 2014 8,561,086 4,420,742 $ 0.23 – 1.89 $ 0.44 Weighted Average Options Shares Price per Price per Outstanding Available share share Balances as of December 31, 2014 8,601,086 4,420,742 $ 0.23 – 1.89 $ 0.44 Granted 940,000 (940,000 ) $ 0.38 – 0.575 0.44 Exercised — — $ — — Expired (200,000 ) — $ 0.575 0.575 Balances as of June 30, 2015 9,341,086 3,480,742 $ 0.23 – 1.89 $ 0.43 Options issued Outside of the 2007 Equity Incentive Plan On June 29, 2015, we issued options to purchase 218,143 shares of our common stock at an exercise price of $0.35 per share to vendors, in lieu of $50,900 in accrued and unpaid fees. The fair value of these options totaled $76,350, resulting in $25,450 of additional selling, general and administrative expenses. On June 29, 2015, we issued options to purchase 192,857 shares of our common stock at an exercise price of $0.35 per share to our members of our board of directors, in lieu of $45,000 in accrued and unpaid fees due for their services on the board. The fair value of these options totaled $67,500, resulting in $22,500 of additional selling, general and administrative expenses. On April 20, 2015, we issued an option to purchase 75,000 shares of our common stock to a consultant. The option is vested at issuance, expires ten years from the date of issuance, and is exercisable at $0.34 per share, the price of our common stock on the grant date was $0.34 per share. The fair value of this option totaled $25,500 and was recorded as selling, general and administrative expense. On April 19, 2015, we issued an option to purchase an aggregate 200,000 shares of our common stock to two consultants. The options vested at issuance, expire ten years from the date of issuance, and are exercisable at $0.37 per share. The price of our common stock on the grant date was $0.34 per share. The fair value of these options totaled $74,000 and was recorded as selling, general and administrative expense. On March 31, 2015, we issued options to purchase 387,676 shares of our common stock at an exercise price of $0.36 per share to two vendors, in lieu of $91,750 in accrued and unpaid fees. The fair value of these options totaled $137,625, resulting in $45,875 of additional selling, general and administrative expenses. On March 30, 2015, we issued options to purchase 190,142 shares of our common stock at an exercise price of $0.36 per share to our members of our board of directors, in lieu of $45,000 in accrued and unpaid fees due for their services on the board. The fair value of these options totaled $68,451, resulting in $23,451 of additional selling, general and administrative expenses. On February 5, 2015, we issued an option to purchase 200,000 shares of our common stock to a consultant. The option vests after a period of ten months from the date of grant, expires ten years from the date of issuance, and is exercisable at $0.33 per share. The fair value of this option totaled $66,000 and is being expensed over the vesting period. On June 24, 2014, we issued options to purchase 103,847 shares of our common stock at an exercise price of $0.65 per share to our board of directors in lieu of $45,000 in accrued and unpaid fees. The fair value of the Options totaled $67,501, resulting in $22,501 of additional selling, general and administrative expenses . On June 24, 2014, we issued options to purchase 148,848 shares of our common stock at an exercise price of $0.65 per share to vendors in lieu of $64,500 in accrued and unpaid fees. The fair value of the Options totaled $96,750, resulting in $32,250 of additional selling, general and administrative expenses . On June 23, 2014, BioLargo, Inc. (the “Company”) and its Chief Financial Officer Charles K. Dargan, II formally agreed to extend the engagement agreement dated February 1, 2008 (the “Engagement Agreement”, which had been previously extended multiple times), pursuant to which Mr. Dargan has been serving as the Company’s Chief Financial Officer. The Engagement Extension Agreement dated as of June 23, 2014 (the “Engagement Extension Agreement”) provides for an additional term to expire January 31, 2015 (the “Extended Term”), and is retroactively effective to February 1, 2014. During the Extended Term, Mr. Dargan shall be compensated through the issuance of an option to purchase 300,000 shares of the Company’s common stock, at a strike price of $0.63 per share, to expire June 23, 2024, and to vest over the term of the engagement with 100,000 shares vested as of June 23, 2014, and the remaining shares to vest 25,000 monthly, provided that the Engagement Extension Agreement with Mr. Dargan has not been terminated prior to each vesting date. During the six-month period ended June 30, 2014, we recorded $78,750 in selling, general and administrative expense for this option. On March 31, 2014, we issued options to purchase 156,888 shares of our common stock at an exercise price of $0.43 per share to our board of directors, in lieu of $45,000 in accrued and unpaid fees. The fair value of the Options totaled $67,461, resulting in $22,461 of additional selling, general and administrative expenses. On March 31, 2014, we issued options to purchase 78,488 shares of our common stock at an exercise price of $0.43 per share to a vendor, in lieu of $22,500 in accrued and unpaid fees. The fair value of the Options totaled $33,750, resulting in $11,250 of additional selling, general and administrative expenses . On February 20, 2014, we issued options to purchase 40,000 shares of our common stock at an exercise price of $0.35 per share, set to expire February 20, 2024, and to vest over the term of the agreement. The fair value of the Options totaled $14,000 of additional selling, general and administrative expenses. Activity of our stock options issued outside of the 2007 Plan for the six-month period ended June 30, 2014 and 2015 is as follows: Weighted Average Options Price per Outstanding Price per share share Balances as of December 31, 2013 16,398,395 $ 0.18 – 1.89 $ 0.41 Granted 816,532 $ 0.43 – 0.65 $ 0.62 Exercised — $ — — Expired — $ — — Balances as of June 30, 2014 17,214,927 $ 0.18 – 1.00 $ 0.39 Options Weighted Average Price per Outstanding Price per share share Balances as of December 31, 2014 17,965,291 $ 0.18 – 1.00 $ 0.39 Granted 1,463,818 $ 0.34 – 0.36 0.35 Exercised — $ — — Expired — $ — — Balances as of June 30, 2015 19,429,109 $ 0.18 – 1.00 $ 0.39 We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the six-month period ended June 30: 2014 2015 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 2.63 – 2.73 % 2.63 % 1.83 – 2.33 % 1.62 - 2.38 % Expected volatility 927 - 935 % 927 % 807 - 821 % 326 - 807 % Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 7 7 3-7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. Historically, we have not had significant forfeitures of unvested stock options granted to employees and Directors. A significant number of our stock option grants are fully vested at issuance or have short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

Note 10 - Accounts Payable and

Note 10 - Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 10. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses included the following: December 31, June 30 , 2014 2015 Accounts payable and accrued expenses $ 313,286 $ 203,622 Uncertain tax position 137,500 137,500 Accrued interest 32,256 53,390 Officer and board of director payables 11,896 49,452 Total accounts payable and accrued expenses $ 494,938 $ 443,964

Note 11 - Non-Controlling Inter

Note 11 - Non-Controlling Interest	6 Months Ended
	Jun. 30, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	Note 11 . Non-Controlling Interest In May 2012, we formed a subsidiary for the purpose of marketing and selling medical products containing our technology, Clyra Medical Technologies, Inc. (“Clyra”). Until December 17, 2012, this subsidiary was wholly owned, with 7,500 shares issued to BioLargo, Inc. On December 17, 2012, Clyra signed executive employment agreements with three individuals, in which each was granted 500 shares of Clyra common stock, one-third of which vested immediately, and the remaining over time. The shares granted to the three executives are restricted from transfer until a sale of the company, whether by means of a sale of its stock or substantially all of its assets, or otherwise by agreement of Clyra, BioLargo and the executives. Clyra sold shares of its common stock (see Note 4). The holdings of the Clyra executive officers and investors represented 19.6% of the issued and outstanding stock of the company as of June 30, 2015. From inception, Clyra has generated no revenues and the financial impact of Clyra’s operations for the six-month period ended June 30, 2015, resulted in a net loss of $57,930.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12. Subsequent Events. Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure. 2015 Unit Offering Subsequent to June 30, 2015, we received $25,000 and issued a convertible promissory note with a maturity date of June 1, 2018 to three investors in our 2015 Unit Offering (see Note 4). Each investor, for no additional consideration, received a stock purchase warrant exercisable at $0.40 per share, which expires June 1, 2020. We issued warrants to purchase an aggregate 420,000 shares. Exercise of Warrants Issued to Clyra Investors Subsequent to June 30, 2015, the final three Clyra investors exercised their BioLargo warrants and tendered 115 shares of Clyra common stock to BioLargo, and were issued an aggregate 460,000 shares of BioLargo common stock.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8-03 of Regulation S-X under the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for annual financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. We are still operating in the early stages of the sales and distribution process, and therefore our operating results for the six-month period ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or for any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2015.
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of: December 31, 2014 June 30, 2015 Raw materials $ 18,816 $ 12,605 Finished goods 6,698 1,996 Total inventory $ 25,514 $ 14,601
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Other Assets Other Assets consists of payments made to purchase patents related to our efforts in commercializing the Isan system. For the six-month periods ended June 30, 2014 and 2015, we recorded amortization expense totaling $5,460 and $5,460, respectively. We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Management has not identified any impairment indicators at June 30, 2015.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based and financing transactions, uncollectible accounts receivable, asset impairment, depreciation and amortization, and taxes, among others.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting. During the six-month periods ended June 30, 2014 and 2015, we recorded an aggregate $442,374 and $655,655 in selling general and administrative expense related to options issued as part of our 2007 Equity Incentive Plan and outside of our 2007 Equity Incentive Plan (see Note 9). During the six-month periods ended June 30, 2014 and 2015, we issued an aggregate 284,491 and 560,921 shares of our common stock to our officers in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $166,607 and $197,732, respectively. During the six-month periods ended June 30, 2014 and 2015, we issued an aggregate 313,209 and 238,904 shares of our common stock to third party vendors in lieu of accrued and unpaid obligations totaling $229,527 and $94,710, respectively. (See Note 9). On March 28, 2014, we issued an aggregate 1,360,000 shares of our common stock to note payable holders in lieu of $584,800 note payable principal balance and related accrued interest. (See Note 5).
Non-Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. License fees are recognized over the estimated period of future benefit to the average licensee. Grants received are recognized as revenue when the terms and conditions of the grant are met on a periodic basis over the life of the grant.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the six-month periods ended June 30, 2014 and 2015, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 creates a new, principle-based revenue recognition framework that will affect all revenue-generating activities. In addition to superseding and replacing nearly all existing revenue recognition guidance under U.S. GAAP, including industry-specific guidance, the new standard: ● changes the basis for deciding when revenue is recognized over time or at a point in time; ● provides new guidance on specific aspects of revenue recognition; and ● expands and improves disclosures about revenue. Entities are required to apply the standard for annual periods beginning after December 15, 2018, and for interim periods therein. The standard permits the use of either the retrospective method, where prior period results are reflected on a comparable basis, or cumulative effect method. Management is currently evaluating the effect of this pronouncement on its financial reporting. In August 2014, the FASB issued ASU No. 2014-15 ("ASU 2014-15"), “Presentation of Financial Statements-Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern.” ASU 2014-15 requires a Company's management to evaluate, at each reporting period, whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory, Topic 330, Inventory.” An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU 2015-11 on its consolidated financial statements. In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02), “Consolidation” . In April 2015, the FASB issued Accounting Standards Update No. 2015-03 (ASU 2015-03), “Interest – Imputation of Interest” (Subtopic 835-30). ASU 2015-03 simplifies the presentation of debt issuance costs and requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the new guidance. ASU 2015-3 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within that fiscal year. Early adoption is permitted for financial statements that have not been previously issued. An entity is required to apply the new guidance on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company is currently evaluating the impact of the adoption of ASU 2015-03 on the Company’s financial statement presentation and disclosures.

Note 2 - Summary of Significa19

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Inventory, Current [Table Text Block]	December 31, 2014 June 30, 2015 Raw materials $ 18,816 $ 12,605 Finished goods 6,698 1,996 Total inventory $ 25,514 $ 14,601

Note 7 - Warrants (Tables)

Note 7 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Warrants [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Price Range Outstanding as of December 31, 2013 10,618,771 $ 0.125 – 2.00 Issued 4,150,001 $ 0.25 – 1.00 Exercised (574,288 ) $ 0.25 – 0.50 Expired (6,111,362 ) $ 0.50 – 1.00 Outstanding as of June 30, 2014 8,083,122 $ 0.125 – 1.00 Number of Shares Price Range Outstanding as of December 31, 2014 8,838,122 $ 0.125 - 1.00 Issued 3,670,976 $ 0.30 - 0.75 Exercised — $ — Expired (2,333,329 ) $ 0.55 Outstanding as of June 30, 2015 10,175,769 $ 0.125 - 1.00
Schedule of Assumptions Used to Determine Fair Value of Warrants [Table Text Block]	2014 2015 Risk free interest rate .15 % 1.32 – 1.71 % Expected volatility 112 % 329 % Expected dividend yield — — Forfeiture rate — — Contractual life in years 1 5

Note 8 - Stock-Based Compensa21

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2014 2015 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 2.63 – 2.73 % 2.63 % 1.83 – 2.33 % 1.62 - 2.38 % Expected volatility 927 - 935 % 927 % 807 - 821 % 326 - 807 % Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 7 7 3-7
The 2007 Equity Incentive Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Options Shares Price per Price per Outstanding Available share share Balances as of December 31, 2013 8,521,086 4,260,742 $ 0.23 – 1.89 $ 0.44 Granted 40,000 (40,000 ) $ 0.63 0.63 Exercised — — $ — — Expired — — $ — — Balances as of June 30, 2014 8,561,086 4,420,742 $ 0.23 – 1.89 $ 0.44 Weighted Average Options Shares Price per Price per Outstanding Available share share Balances as of December 31, 2014 8,601,086 4,420,742 $ 0.23 – 1.89 $ 0.44 Granted 940,000 (940,000 ) $ 0.38 – 0.575 0.44 Exercised — — $ — — Expired (200,000 ) — $ 0.575 0.575 Balances as of June 30, 2015 9,341,086 3,480,742 $ 0.23 – 1.89 $ 0.43
Outside of 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Options Price per Outstanding Price per share share Balances as of December 31, 2013 16,398,395 $ 0.18 – 1.89 $ 0.41 Granted 816,532 $ 0.43 – 0.65 $ 0.62 Exercised — $ — — Expired — $ — — Balances as of June 30, 2014 17,214,927 $ 0.18 – 1.00 $ 0.39 Options Weighted Average Price per Outstanding Price per share share Balances as of December 31, 2014 17,965,291 $ 0.18 – 1.00 $ 0.39 Granted 1,463,818 $ 0.34 – 0.36 0.35 Exercised — $ — — Expired — $ — — Balances as of June 30, 2015 19,429,109 $ 0.18 – 1.00 $ 0.39

Note 10 - Accounts Payable an22

Note 10 - Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, June 30 , 2014 2015 Accounts payable and accrued expenses $ 313,286 $ 203,622 Uncertain tax position 137,500 137,500 Accrued interest 32,256 53,390 Officer and board of director payables 11,896 49,452 Total accounts payable and accrued expenses $ 494,938 $ 443,964

Note 1 - Business and Organiz23

Note 1 - Business and Organization (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Disclosure Text Block [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (1,299,968)	$ (1,071,942)	$ (1,995,086)	$ (2,145,012)
Net Assets	(545,517)		(545,517)
Assets, Current	164,105		164,105		$ 230,591
Retained Earnings (Accumulated Deficit)	(81,003,461)		(81,003,461)		(79,019,719)
Cash and Cash Equivalents, at Carrying Value	96,948	318,318	96,948	318,318	154,460	$ 92,437
Revenues	39,843	$ 21,086	66,514	$ 30,373
Long-term Debt, Gross	1,042,919		1,042,919
Accounts Payable and Accrued Liabilities, Current	$ 443,964		$ 443,964		$ 494,938

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 28, 2014	Mar. 26, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		1,360,000
Accrued and Unpaid Salary and Unreimbursed Expenses [Member] | Officers [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)			560,921	284,491
Stock Issued During Period, Value, Issued for Services			$ 197,732	$ 166,607
Accrued and Unpaid Salary and Unreimbursed Expenses [Member] | Third-Party Vendors [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)			238,904	313,209
Stock Issued During Period, Value, Issued for Services			$ 94,710	$ 229,527
Note Payable Principal Balance and Related Accrued Interest [Member] | Note Payable Holders [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,360,000
Debt Conversion, Original Debt, Amount	$ 584,800
Selling, General and Administrative Expenses [Member] | Part of 2007 Equity Incentive Plan and Options Issued Outside of 2007 Equity Incentive Plan [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Allocated Share-based Compensation Expense			655,655	442,374
Patents [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Amortization of Intangible Assets			$ 5,460	$ 5,460

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Details) - Inventories - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventories [Abstract]
Raw materials	$ 12,605	$ 18,816
Finished goods	1,996	6,698
Total inventory	$ 14,601	$ 25,514

Note 3 - Deposit (Details)

Note 3 - Deposit (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2012	Dec. 31, 2014	Feb. 28, 2014
Note 3 - Deposit (Details) [Line Items]
Customer Deposits, Current (in Dollars)	$ 100,000		$ 100,000
Peter Holdings Ltd. [Member]
Note 3 - Deposit (Details) [Line Items]
Joint Venture, Royalties, Percentage		50.00%
Licensing Agreements [Member] | Clarion Water [Member] | Isan System License Agreement [Member] | Peter Holdings Ltd. [Member]
Note 3 - Deposit (Details) [Line Items]
Customer Deposits, Current (in Dollars)				$ 100,000
Royalty as Percentage of Sales	10.00%
Royalty as Percentage of Sublicensing Fees	40.00%
Licensing Agreements [Member] | Clarion Water [Member] | Isan System License Agreement [Member] | Beginning July 1, 2016 [Member] | Peter Holdings Ltd. [Member]
Note 3 - Deposit (Details) [Line Items]
Quarterly Payments from Licensee (in Dollars)	$ 50,000

Note 4 - Private Securities O27

Note 4 - Private Securities Offerings (Details) - USD ($)	Jan. 15, 2015	Mar. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Jun. 30, 2015	Jan. 31, 2015	Mar. 26, 2014	Feb. 02, 2014
Note 4 - Private Securities Offerings (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Warrant Term	30 days
Share Price (in Dollars per share)								$ 0.43
Debt Instrument, Convertible, Conversion Price (in Dollars per share)								$ 0.25
Common Stock, Shares Authorized (in Shares)					200,000,000	200,000,000
2015 Unit Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Maximum Discount on Securities Offering	30.00%
Debt Instrument, Interest Rate, Stated Percentage					12.00%	12.00%	12.00%
Warrant Term					3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$ 0.30	$ 0.40	$ 0.30
2015 Unit Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Over-Allotment Percentage	20.00%
Maximum Over-Allotment Amount	$ 1,000,000
Unit Offering Maximum Value	6,000,000
Minimum Proceeds Required for Stock Registration	$ 3,000,000
Summer 2013 [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)		$ 0.25		$ 0.25
Proceeds from Issuance of Private Placement		$ 767,500		$ 842,500
Proceeds from Issuance of Private Placement Net				837,000
Common Stock, Value, Subscriptions		$ 20,000		$ 20,000
Stock Issued During Period, Shares, New Issues (in Shares)		3,110,000		3,370,000
Payments of Stock Issuance Costs		$ 15,500
Accrued Private Placement Fees		$ 34,600
Stock Issuance Cost Paid In Shares, Shares (in Shares)		138,400
Shares Issued, Price Per Share (in Dollars per share)		$ 0.25		$ 0.25
Share Price (in Dollars per share)		$ 0.47		$ 0.47
Additional Expense, Market Share Price in Excess of Issuance Price		$ 65,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)						$ 0.60
Clyra Spring 2014 Private Securities Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Sale of Stock, Price Per Share (in Dollars per share)									$ 1,000
Proceeds from Issuance of Private Placement			$ 220,000
Stock Issued During Period, Shares, New Issues (in Shares)			220
Common Stock, Shares Authorized (in Shares)									1,000
Common Stock [Member] | Clyra Spring 2014 Private Securities Offering [Member]
Note 4 - Private Securities Offerings (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$ 1,833.33
Warrant, Number of Parent Shares Received for One Share of Subsidiary (in Shares)									4,000

Note 5 - Notes and Convertibl28

Note 5 - Notes and Convertible Notes Payable (Details) - USD ($)	Jan. 15, 2015	Mar. 26, 2014	Nov. 19, 2013	Dec. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Jun. 17, 2015	Apr. 27, 2015	Jan. 31, 2015
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Warrant Term	30 days
Proceeds from Lines of Credit			$ 50,000
Line of Credit Facility, Interest Rate at Period End			24.00%
Interest Expense, Debt		$ 65,000			$ 317,075	$ 64,665
2015 Unit Offering [Member]
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Proceeds from Issuance of Debt				$ 200,000	$ 645,000
Debt Instrument, Interest Rate, Stated Percentage				12.00%	12.00%		12.00%			12.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 0.30	$ 0.40		$ 0.30			$ 0.30
Debt Instrument, Term				3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)				350,000			350,000
				$ 200,000			$ 200,000
Debt Instrument, Face Amount										$ 133,000
Warrant Term							3 years
April 2015 Warrants [Member] | 2015 Unit Offering [Member]
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)									226,440
Debt Instrument, Face Amount									$ 56,610
June 2015 Warrants [Member] | 2015 Unit Offering [Member]
Note 5 - Notes and Convertible Notes Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)								233,236
Debt Instrument, Face Amount								$ 58,309

Note 6 - Conversion of Notes (D

Note 6 - Conversion of Notes (Details) - USD ($)	Mar. 26, 2014	Jun. 30, 2015	Jun. 30, 2014
Conversion Of Notes [Abstract]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,360,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.25
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 584,800
Debt Conversion, Converted Instrument, Amount	275,000
Interest Expense, Debt	$ 65,000	$ 317,075	$ 64,665
Share Price (in Dollars per share)	$ 0.43
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	$ 244,800

Note 7 - Warrants (Details)

Note 7 - Warrants (Details) - USD ($)	Jul. 01, 2015	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 7 - Warrants (Details) [Line Items]
Short-term Debt, Refinanced, Amount (in Dollars)			$ 114,919
Conversion of Notes Payable [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			266,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.30
(in Dollars)			$ 133,000
Issued in Conjunction with the Extension of Convertible Note Payable [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			459,676
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.40
(in Dollars)			$ 114,919
2015 Unit Offering [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,732,800
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.40
(in Dollars)			$ 645,000
Summer 2013 [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,370,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.30
Stock Issued During Period, Shares, New Issues		3,110,000
Clyra Spring 2014 Private Securities Offering [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				880,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 1,833.33
Clyra 2014 Warrants [Member] | Two Clyra Shareholders [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			75
Stock Issued During Period, Shares, Conversion of Convertible Securities			300,000
Clyra 2014 Warrants [Member] | Subsequent Event [Member] | Final Three Clyra Shareholders [Member]
Note 7 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	115
Stock Issued During Period, Shares, Conversion of Convertible Securities	460,000

Note 7 - Warrants (Details) - W

Note 7 - Warrants (Details) - Warrants Outstanding - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Number of Shares (in Shares)	10,175,769	8,083,122
Shares Issued (in Shares)	3,670,976	4,150,001
Shares Exercised (in Shares)		(574,288)
Shares Expired (in Shares)	(2,333,329)	(6,111,362)
Expired Price Range	$ 0.55
Minimum [Member]
Class of Warrant or Right [Line Items]
Price Range	0.125	$ 0.125
Issued Price Range	0.30	0.25
Exercised Price Range		0.25
Expired Price Range		0.50
Maximum [Member]
Class of Warrant or Right [Line Items]
Price Range	1	1
Issued Price Range	$ 0.75	1
Exercised Price Range		0.50
Expired Price Range		$ 1

Note 7 - Warrants (Details) - A

Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants - Warrant [Member]	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate		0.15%
Expected volatility	329.00%	112.00%
Contractual life in years	5 years	1 year
Minimum [Member]
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate	1.32%
Maximum [Member]
Note 7 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]
Risk free interest rate	1.71%

Note 8 - Stock-Based Compensa33

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - USD ($)

Jun. 29, 2015

Jun. 24, 2015

Apr. 20, 2015

Apr. 19, 2015

Mar. 31, 2015

Mar. 30, 2015

Feb. 05, 2015

Jun. 24, 2014

Jun. 23, 2014

Mar. 31, 2014

Feb. 20, 2014

Jun. 30, 2015

Jun. 30, 2014

Mar. 26, 2014

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

940,000

40,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.44

$ 0.63

Share Price (in Dollars per share)

$ 0.43

Employee Stock Option [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate

0.00%

Part of 2007 Equity Incentive Plan and Options Issued Outside of 2007 Equity Incentive Plan [Member] | Selling, General and Administrative Expenses [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 655,655

$ 442,374

The 2007 Equity Incentive Plan [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

700,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.40

Share Price (in Dollars per share)

$ 0.34

Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value

$ 238,000

The 2007 Equity Incentive Plan [Member] | Chief Technology Officer [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

200,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expiration Period, Extension

5 years

The 2007 Equity Incentive Plan [Member] | Board of Directors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

40,000

The 2007 Equity Incentive Plan [Member] | Selling, General and Administrative Expenses [Member] | Chief Technology Officer [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 68,000

The 2007 Equity Incentive Plan [Member] | Selling, General and Administrative Expenses [Member] | Board of Directors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 15,200

The 2007 Equity Incentive Plan [Member] | Board of Directors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

40,000

The 2007 Equity Incentive Plan [Member] | Board of Directors [Member] | Selling, General and Administrative Expenses [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 25,200

The 2007 Equity Incentive Plan [Member] | Director [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.63

The 2007 Equity Incentive Plan [Member] | Employee Stock Option [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

The 2007 Equity Incentive Plan [Member] | Employee Stock Option [Member] | Director [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.38

Outside of the 2007 Plan [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

40,000

1,463,818

816,532

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.35

$ 0.35

$ 0.62

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 14,000

Outside of the 2007 Plan [Member] | Chief Technology Officer [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.575

Outside of the 2007 Plan [Member] | Board of Directors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.65

Outside of the 2007 Plan [Member] | A Consultant [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

75,000

200,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.34

$ 0.33

Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value

$ 66,000

Outside of the 2007 Plan [Member] | Consultants 1 and 2 [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

200,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.37

Share Price (in Dollars per share)

$ 0.34

Outside of the 2007 Plan [Member] | Consultant 2 [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

200,000

Outside of the 2007 Plan [Member] | Selling, General and Administrative Expenses [Member] | A Consultant [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 25,500

Outside of the 2007 Plan [Member] | Selling, General and Administrative Expenses [Member] | Consultants 1 and 2 [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 74,000

Outside of the 2007 Plan [Member] | Board of Directors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

192,857

190,142

103,847

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.35

$ 0.36

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 67,500

$ 68,451

$ 67,501

$ 67,461

Outside of the 2007 Plan [Member] | Board of Directors [Member] | Accrued and Unpaid Obligations [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

156,888

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.43

Other Liabilities, Current

45,000

45,000

$ 45,000

Outside of the 2007 Plan [Member] | Board of Directors [Member] | Selling, General and Administrative Expenses [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 22,500

$ 23,451

$ 22,461

Outside of the 2007 Plan [Member] | Board of Directors [Member] | Selling, General and Administrative Expense [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 22,501

Outside of the 2007 Plan [Member] | Vendors [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

218,143

387,676

148,848

78,488

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.35

$ 0.36

$ 0.65

$ 0.43

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 76,350

$ 137,625

$ 96,750

$ 33,750

Outside of the 2007 Plan [Member] | Vendors [Member] | Accrued and Unpaid Obligations [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Other Liabilities, Current

50,900

91,750

64,500

22,500

Outside of the 2007 Plan [Member] | Vendors [Member] | Selling, General and Administrative Expenses [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 25,450

$ 45,875

$ 32,250

$ 11,250

Outside of the 2007 Plan [Member] | Chief Financial Officer [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

300,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 0.63

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)

100,000

Outside of the 2007 Plan [Member] | Chief Financial Officer [Member] | Vesting Monthly [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)

25,000

Outside of the 2007 Plan [Member] | Chief Financial Officer [Member] | Selling, General and Administrative Expenses [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 78,750

Outside of the 2007 Plan [Member] | Employee Stock Option [Member] | A Consultant [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

10 months

Outside of the 2007 Plan [Member] | Employee Stock Option [Member] | Consultants 1 and 2 [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Note 8 - Stock-Based Compensa34

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Options Outstanding (in Shares)	9,341,086	8,561,086
Shares Available (in Shares)	3,480,742	4,420,742
Average Price per Share	$ 0.43	$ 0.44
Granted (in Shares)	940,000	40,000
Granted, Shares Available (in Shares)	(940,000)	(40,000)
Granted, Exercise Price per Share		$ 0.63
Granted, Average Price per Share	$ 0.44	0.63
Options Expired (in Shares)	(200,000)
Exercise Price per Share, Expired	$ 0.575
Average Price per Share, Expired	0.575
Minimum [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Exercise Price per Share	0.23	0.23
Granted, Exercise Price per Share	0.38
Maximum [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options Activity [Line Items]
Exercise Price per Share	1.89	$ 1.89
Granted, Exercise Price per Share	$ 0.575

Note 8 - Stock-Based Compensa35

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan - $ / shares	Feb. 20, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Options Outstanding (in Shares)		9,341,086	8,561,086
Weighted Average Price per Share		$ 0.43	$ 0.44	$ 0.44	$ 0.44
Options Granted (in Shares)		940,000	40,000
Exercise Price per Share, Granted			$ 0.63
Weighted Average Price per Share, Granted		$ 0.44	$ 0.63
Outside of the 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Options Outstanding (in Shares)		19,429,109	17,214,927
Weighted Average Price per Share		$ 0.39	$ 0.39	$ 0.39	$ 0.41
Options Granted (in Shares)	40,000	1,463,818	816,532
Weighted Average Price per Share, Granted	$ 0.35	$ 0.35	$ 0.62
Minimum [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share		0.23	0.23
Exercise Price per Share, Granted		0.38
Minimum [Member] | Outside of the 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share		0.18	0.18
Exercise Price per Share, Granted		0.34	0.43
Maximum [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share		1.89	1.89
Exercise Price per Share, Granted		0.575
Maximum [Member] | Outside of the 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]
Exercise Price per Share		1	1
Exercise Price per Share, Granted		$ 0.36	$ 0.65

Note 8 - Stock-Based Compensa36

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Non Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate		2.63%
Expected volatility		927.00%
Expected life in years	7 years	7 years
Minimum [Member] | Non Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate	1.83%	2.63%
Expected volatility	807.00%	927.00%
Minimum [Member] | 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate	1.62%
Expected volatility	326.00%
Expected life in years	3 years
Maximum [Member] | Non Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate	2.33%	2.73%
Expected volatility	821.00%	935.00%
Maximum [Member] | 2007 Plan [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]
Risk free interest rate	2.38%
Expected volatility	807.00%
Expected life in years	7 years

Note 10 - Accounts Payable an37

Note 10 - Accounts Payable and Accrued Expenses (Details) - Accounts Payable and Accrued Expenses - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable and accrued expenses	$ 203,622	$ 313,286
Uncertain tax position	137,500	137,500
Accrued interest	53,390	32,256
Officer and board of director payables	49,452	11,896
Total accounts payable and accrued expenses	$ 443,964	$ 494,938

Note 11 - Non-Controlling Int38

Note 11 - Non-Controlling Interest (Details) - USD ($)	Dec. 17, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	May. 31, 2012
Note 11 - Non-Controlling Interest (Details) [Line Items]
Sale of Stock, Percentage of Ownership after Transaction				19.60%
Revenues		$ 39,843	$ 21,086	$ 66,514	$ 30,373
Net Income (Loss) Attributable to Noncontrolling Interest		$ (5,588)	$ (14,122)	(11,344)	$ (24,205)
Clyra Medical Technology, Inc. [Member]
Note 11 - Non-Controlling Interest (Details) [Line Items]
Investment Owned, Balance, Shares						7,500
Revenues				0
Net Income (Loss) Attributable to Noncontrolling Interest				$ (57,930)
Each of 3 Individuals [Member] | Clyra Medical Technology, Inc. [Member]
Note 11 - Non-Controlling Interest (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	500

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details) - USD ($)	Jul. 01, 2015	Jun. 30, 2015	Jan. 31, 2015	Dec. 31, 2014
2015 Unit Offering [Member]
Note 12 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.40	$ 0.30	$ 0.30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				350,000
Subsequent Event [Member] | 2015 Unit Offering [Member]
Note 12 - Subsequent Events (Details) [Line Items]
Proceeds from Convertible Debt (in Dollars)	$ 25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	420,000
Clyra 2014 Warrants [Member] | Subsequent Event [Member] | Final Three Clyra Shareholders [Member]
Note 12 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	115
Stock Issued During Period, Shares, Conversion of Convertible Securities	460,000

Uncategorized Items - blgo-2015

Label	Element	Value
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4,260,742
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4,420,742
Class of Warrant or Right, Outstanding	us-gaap_ClassOfWarrantOrRightOutstanding	10,618,771
Class of Warrant or Right, Outstanding	us-gaap_ClassOfWarrantOrRightOutstanding	8,838,122
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8,521,086
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8,601,086
Maximum [Member]
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	$ 1.89
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	1.89
PriceRangeWarrantsOutstanding	blgo_PriceRangeWarrantsOutstanding	1
PriceRangeWarrantsOutstanding	blgo_PriceRangeWarrantsOutstanding	2
Minimum [Member]
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	0.23
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	0.23
PriceRangeWarrantsOutstanding	blgo_PriceRangeWarrantsOutstanding	0.125
PriceRangeWarrantsOutstanding	blgo_PriceRangeWarrantsOutstanding	$ 0.125
Outside Of The 2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16,398,395
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17,965,291
Outside Of The 2007 Plan [Member] | Maximum [Member]
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	$ 1
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	1.89
Outside Of The 2007 Plan [Member] | Minimum [Member]
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	0.18
StockOptionsExercisePriceRange	blgo_StockOptionsExercisePriceRange	$ 0.18